Internal Medicine, Hematology · Cleveland, OH
NPI
1336303817
Since 2008
Specialty
Internal Medicine, Hematology
Code 207RH0000X
Group practices
3
Medicare group memberships
Hospitals
4
Hospital affiliations
11100 Euclid Ave
Cleveland, OH, 44106
Phone (216) 407-5753
Groups this clinician bills Medicare through
Medicare paid, 2024
$25K
367 services
Medicare patients, 2024
146
Average age 74
Drug cost, 2024
$4.6M
784 prescriptions
Company payments, 2025
$252
From 7 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Leland L Metheny III was code 99233 (hospital e&m - subsequent), 133 times for 30 patients. In total Leland L Metheny III billed 367 services in 14 codes, and Medicare paid $25K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-01-11.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99233 Hospital E&M - Subsequent | Facility | 133 | 30 | $88.34 | $12K |
| 99213 Office E&M - Established | Facility | 75 | 59 | $44.71 | $3,354 |
| 99214 Office E&M - Established | Facility | 61 | 40 | $64.61 | $3,941 |
| 99442 Telephone Services | Facility | 33 | 21 | $43.94 | $1,450 |
| 99221 Hospital E&M - Initial | Facility | 17 | 15 | $55.54 | $944 |
| 99239 Hospital Discharge Management | Facility | 13 | 12 | $86.62 | $1,126 |
By year: 2022 $24K for 313 services; 2023 $27K for 342 services; 2024 $25K for 367 services.
Medicare prescription drug claims, 2024
In 2024, the drug Leland L Metheny III prescribed most often to Medicare patients was Imbruvica (Ibrutinib), with 91 prescriptions and refills. In total Leland L Metheny III wrote 784 Medicare prescriptions that cost $4.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Imbruvica Ibrutinib | 91 | 91 | Under 11 | $1.5M |
| Calquence Acalabrutinib Maleate | 79 | 79 | Under 11 | $1.0M |
| Acyclovir Generic | 77 | 150 | 29 | $1,144 |
| Hydroxyurea Generic | 59 | 128 | 14 | $1,602 |
| Venclexta Venetoclax | 38 | 38 | 11 | $223K |
| Onureg Azacitidine | 34 | 34 | Under 11 | $813K |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 25 | 54 | 13 | $208 |
| Prochlorperazine Maleate Generic | 22 | 22 | 15 | $270 |
| Xarelto Rivaroxaban | 20 | 22 | Under 11 | $12K |
| Jakafi Ruxolitinib Phosphate | 16 | 16 | Under 11 | $209K |
| Ondansetron Hcl Generic | 16 | 16 | Under 11 | $131 |
| Gabapentin Generic | 14 | 19 | Under 11 | $128 |
| Pantoprazole Sodium Generic | 13 | 21 | Under 11 | $68.02 |
| Duloxetine Hcl Generic | 12 | 18 | Under 11 | $231 |
| Eliquis Apixaban | 12 | 12 | Under 11 | $7,104 |
Brand drugs: 343 claims; generic drugs: 441 claims; opioid claims: 13.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Leland L Metheny III $252 ($252 in general payments such as food, travel and fees) from 7 companies. The largest payer was Incyte Corporation with $125.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.